
Wait Times to See Physicians Continue to Climb
Your patient has waited 4 weeks for a 15-minute visit, and you're double-booked and distracted. As physician shortages collide with rising demand, wait times have increased, and appointment delays are the norm, not the exception. Patients are frustrated, and physicians are overwhelmed.
In fact, according to a new survey conducted by AMN Healthcare, the average physician appointment wait time in 15 major metropolitan areas has increased by 19% since the survey was last conducted in 2022 and by 48% since it was first conducted in 2004. This translates to patients waiting 31 days on average to book time with a healthcare provider, up from 26 days in 2022 and 21 days in 2004.
Medscape continually surveys physicians and other medical professionals about key practice challenges and current issues, creating high-impact analyses. For example, Medscape's Artificial Intelligence (AI) Adoption in Healthcare Report 2024 found that Just 18% of physician offices use AI to create staff schedules, yet 30% predict they'll use AI for this in the future.
19% of physician offices use AI for patient census predictions, yet 40% predict they'll use AI for this in the future.
One big surprise about the survey is that appointment wait times weren't even longer, Jeff Decker, president of AMN's physician and leadership solutions division, told Medscape Medical News , adding that in Boston, wait times were the longest (65 days), while Atlanta had the shortest wait times (12 days).
'Anecdotally, we've heard of physician appointment wait times that commonly extend 2 or 3 months or more rather than a few weeks or 1 month,' Decker said. 'We think this may be a result of medical practice consolidation, where more physicians are part of large medical groups than has been the case in the past.'
In addition, wait times can vary based on whether (or not) the physician accepts Medicare or Medicaid and tend to be even longer when new patients book an appointment with a specialist. The survey found there was a 42-day wait for obstetricians and gynecologists (ob/gyns), a 40-day wait for gastroenterologists, and a 36.5-day wait for dermatologists, something Dara Spearman, MD, a board-certified dermatologist in private practice in Fort Wayne, Indiana, said sounds accurate.
'There are fewer than 10 dermatologists in Fort Wayne, so this creates quite a backlog,' she said. 'Because dermatologists can treat over 3000 diseases, I'm trying to triage a bit and see if we can overlap with other specialties, like having pediatricians or primary care start treatments for a patient with acne, to leave room for patients who need to see us immediately.'
Appointment times for serious cases, such as the skin cancers she sees among her farmer patient population, are Spearman's greatest priority.
'When you're talking about melanoma, time is of the essence,' she said. 'Patients have to get in quickly to get it recognized, and the earlier you get it out, the less likely it is to spread. That's why I use the Secure Chat feature on Epic. This way, when primary care reaches out about something they're worried about, I can get that patient in as fast as possible.'
Like Spearman, physicians around the country are coming up with other unique solutions to make sure they can get patients into the office as quickly as their schedules will allow.
For one, partnering with other professionals can open up patient appointment slots, and many medical practices today, both in primary care and in specialty areas, are using advanced practice professionals to do just that.
'Medical practices are using locum tenens physicians to extend services and patient access, particularly during peak usage periods,' AMN's Decker said. 'Working alongside nurse practitioners (NPs) and physician assistants (PAs) will also ease their workload and free up their time.'
Partnering with NPs was exactly what Ashish Nanda, MD, director of Stroke and Neuro-Interventional at Providence Health System in Orange County, California, proposed to his hospital as he sketched out the creation of a stroke clinic there, which will open in August 2025.
'I realized that our stroke patients were getting discharged but needed follow-up to prevent another one from occurring,' Nanda said. 'The only way to do that was to see them in clinic, so I proposed a dedicated stroke clinic staffed by one specialist and one NP. With two clinicians, we can see more volume and make sure appointments are easier to book.'
Another way to boost efficiency is to 'divide and conquer' health conditions within your own practice.
'For example, one partner in the practice can do skin cancer evaluations while the other can focus on complex dermatology procedures,' Spearman said. 'That can be boring for some physicians, but this can really help with scheduling.'
This is something Spearman has observed among her ob/gyn colleagues.
'As ob/gyns get older, many are done with the OB life of being on-call,' she said. 'They can opt to focus instead on pelvic disorders or endometriosis. By rethinking how your practice is run, you can streamline the process for patients, too.'
Ultimately, the physicians Medscape Medical News spoke with agree that technology will be the ultimate solution to the extensive physician wait times patients are currently experiencing.
'Right now, physicians are spending 50% of their day on administration, whether it's writing notes, following up on labs, and documenting visits, which means they can't see the many patients that need to be seen in a day,' Nanda said.
In turn, if AI can cut that administrative time down to 10%, it means a physician can double the number of patients they see, which will ease the current bottleneck, added Samuel R. Browd, MD, PhD, professor of neurological surgery at the University of Washington and attending neurosurgeon at Seattle Children's Hospital in Seattle.
'Our hope is that the emergence of new technology that's clumped under AI is going to create the ability to have more efficiency within the system and allow the current number of providers to be able to scale what they're able to do,' Browd said. 'I'm doing clinic today and probably spend half of the time, if not more, managing Epic, doing paperwork, and documenting visits instead of engaging with patients.'
The goal is for AI-powered documentation tools to become more and more of a norm in the hopes that this will help lessen administrative tasks.
'The more burdened we are, the less quality care we can deliver,' Browd said. 'The hope is that with AI and other emerging tools, we can create a better work environment, too.'
Happily, Browd says technology is moving rapidly, which may mean that within the next 3-5 years, it will become increasingly easier to make a doctor's appointment — quickly and efficiently.
'If you fast forward to 5 years down the road, what we do day-to-day will be significantly different and will be beneficial in terms of enabling patients to have better access to care,' he said.
This will improve the caregiving experience for physicians, too.
'My hope is that this will also change the work environment for doctors in a positive way,' Browd said. 'This will allow us to get back to being doctors, back to the things that brought us into the field in the first place — like taking our time to care for and listen to patients.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News24
23 minutes ago
- News24
Twice-a-year R500k HIV prevention shot wins US approval
Gilead Sciences said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people. In two big international studies published last year, the medicine demonstrated a powerful ability to avert HIV infection. With no vaccine on the horizon, the ultra-long acting shot has been hailed by activists as perhaps the best tool the world has so far to wipe out the virus. The medicine will be marketed as Yeztugo, Gilead said, and will have a list price of $28 218 (R509 000) per year. That compares to a list price of about $26 400 per year for Descovy, the company's daily pill for HIV prevention. Shares of Gilead briefly jumped as much as 3.5%, their biggest gain in almost a month. The stock had risen 17% this year through Tuesday, outperforming a 2% increase in the S&P 500 index. Even as it works to make the drug a bestseller in rich countries like the US, the Foster City, California-based company will face great pressure to rapidly roll it out for poor and middle income countries that have been hit hard by HIV. 'This is a milestone moment in the decades-long fight against HIV,' Gilead Chief Executive Officer Daniel O'Day said in an emailed statement. 'We now have a way to end the HIV epidemic.' The approval and rollout of the drug will being closely watched by Wall Street, which is hoping it will provide a new source of growth to turbocharge Gilead's mature portfolio of pills for HIV and hepatitis C. It's expected to surpass $4 billion in annual sales by 2031, according to analysts surveyed by Bloomberg. It will compete with Apretude, a prevention shot from ViiV Healthcare, majority-owned by GSK Plc, that's given every other month. While the incidence of HIV has declined since its peak in the 1990s, some 1.3 million people are infected with the virus each year. Some of the highest rates of new cases occur in various countries in Africa. And while daily prevention pills work, they have downsides. People can forget to take them. Others may not want to get them because of the stigma surrounding HIV, or because they worry the pill bottle may inadvertently divulge their high-risk status. Gilead has filed for approval in numerous places, including South Africa, Brazil, Australia, Canada, the European Union, and the EU Medicines For All programme, which helps speed the review of drugs that will be used in developing countries. In one large international trial published last November in men and transgender people, the drug prevented all but two HIV cases among 2 180 people given it, a rate 96% lower than the background incidence level in that population. It was also superior to the company's old HIV prevention pill Truvada. And in June, Gilead said a trial of the shot in women and adolescent girls in Africa prevented 100% of HIV cases, a result the company said was unprecedented. Side effects include injection site reactions, which caused 1.2% of people in one study to stop taking it. Gilead already sells the same drug, lenacapavir, as a treatment for people with multidrug-resistant HIV under the brand Sunlenca.

Associated Press
39 minutes ago
- Associated Press
ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery Patient Treatments in Latin America
SAN CARLOS, Calif.--(BUSINESS WIRE)--Jun 19, 2025-- ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia ( ) has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region. This press release features multimedia. View the full release here: The ZAP-X® Gyroscopic Radiosurgery® platform at Radioterapia Concordia, Neuland, Boquerón, Paraguay In its first day of operation, four patients received next-generation stereotactic radiosurgery (SRS) with ZAP-X® for a range of intracranial conditions, including meningioma, acoustic neuroma, trigeminal neuralgia, and arteriovenous malformation (AVM). Historically, patients in the central regions of Latin America have had limited or no access to modern SRS, often requiring travel to large metropolitan hubs like Buenos Aires, São Paulo, or Santiago. Radioterapia Concordia now offers these advanced treatments locally, helping bridge a longstanding healthcare gap for rural communities. 'People in rural areas deserve to receive world-class medical care where they live, from people they understand, and at a fair price,' said Prof. Dr. Peter Douglas Klassen, Founder of Saludconcordia SA. 'With ZAP-X, we are bringing the most advanced SRS capabilities to communities that have long been underserved.' The creation of Radioterapia Concordia is further bolstered by its strategic location along the Bi-Oceanic Corridor—a transformative infrastructure project linking Brazil, Paraguay, Argentina, and Chile to improve regional access and trade. The new cancer center also benefits from its collaborative relationship with ZAP-X Zentrum Lingen in Germany, home to Europe's first ZAP-X system. 'This is more than just a technology deployment—it's a movement toward cooperative medicine,' said MBA MSc Edelgard Loewen, Case Manager at ZAP-X Zentrum Lingen. 'We're witnessing a new model emerge in Latin America—one that rises above the limitations of national and purely private healthcare systems to prioritize patients through altruistic, turnkey cancer care.' As an alternative to open brain surgery, stereotactic radiosurgery is a non-invasive, outpatient procedure used to treat many primary and metastatic brain tumors, as well as other disorders of the head and neck. Unlike traditional surgery however, SRS does not require incisions or anesthesia, and patients often return to normal activities the same day. The ZAP-X system is renowned for its unique gyroscopic design, which enables the delivery of radiosurgical beams from thousands of unique angles. This approach enhances the ability to concentrate radiation precisely on the tumor while minimizing dose to surrounding healthy brain tissue—an important factor in preserving cognitive function. ZAP-X is also the first and only vault-free SRS system, removing the need for costly shielded treatment rooms. Additionally, by utilizing a modern linear accelerator, ZAP-X eliminates the use of Cobalt-60, avoiding the exorbitant costs and regulatory burdens tied to radioactive isotopes. For more information about ZAP Surgical and the ZAP-X system, visit About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn. View source version on CONTACT: Mark Arnold, ZAP Surgical Systems, Inc. Senior Vice President, Marketing +1 650 492 7797, ext. 101 Email:[email protected] KEYWORD: LATIN AMERICA NORTH AMERICA UNITED STATES PARAGUAY SOUTH AMERICA CALIFORNIA INDUSTRY KEYWORD: NEUROLOGY RADIOLOGY SURGERY ONCOLOGY HEALTH MEDICAL DEVICES HOSPITALS OTHER HEALTH SOURCE: ZAP Surgical Systems, Inc. Copyright Business Wire 2025. PUB: 06/19/2025 07:15 AM/DISC: 06/19/2025 07:15 AM


Medscape
43 minutes ago
- Medscape
Post-Acute COVID Biomarker Patterns Vary by Symptom and Time
In patients with post-acute sequelae of SARS-CoV-2 infection (PASC), biomarker profiles varied according to symptom type and time since infection, and levels of inflammatory biomarkers (IFN gamma and CD163) and vascular activation biomarkers (VCAM-1 and ICAM-1) showed strong correlations with specific long-COVID symptoms. METHODOLOGY: PASC affects a considerable number of people after mild acute SARS-CoV-2 infection, but data on its pathophysiologic mechanisms remain limited. In this study, researchers explored symptoms associated with PASC and examined its association with a range of blood biomarkers. They included participants with prior SARS-CoV-2 infection either asymptomatic or without persistent symptoms categorized into recovered (n = 490) and PASC (n = 311) groups, using data from three French population-based cohorts collected between February 2020 and October 2021. Participants received two home visits at baseline and 6 months for biological sample collection and completed questionnaires covering medical history, infection status, vaccination status, symptoms, and mental health. Researchers assessed 14 blood biomarkers, including cytokines, chemokines, immune checkpoints, cell adhesion molecules, and markers of macrophage activation and vascular damage, which are known to be involved in the pathophysiologic mechanisms of SARS-CoV-2 infection. TAKEAWAY: Participants with PASC commonly reported persistent fatigue, breathlessness, cough, and sleep disorders, along with higher rates of depression and anxiety. Inflammatory biomarkers linked to COVID-19 severity (IFN gamma and CD163) and vascular activation markers (VCAM-1 and ICAM-1) showed significant correlations with specific PASC symptoms, particularly among participants infected within the past year; however, these associations largely disappeared over time. Viral activation markers (PD-L1 and IP-10) were positively associated with acute-phase symptoms such as anosmia/ageusia and cough, particularly in recent infections. Complete symptom resolution was more common among participants with recent infections (< 1 year ago) than among those infected a year ago, occurring in 38% vs 20% of cases ( P = .04). Overall, 74% of individuals experienced a resolution of at least one symptom. IN PRACTICE: 'Biomarker profiles appear to vary according to symptom type and the time elapsed since infection. Consequently, research efforts and treatment strategies should take these parameters into account,' the authors wrote. SOURCE: This study was led by Olivier Robineau, Sorbonne Université, Inserm, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Paris, France. It was published online on May 30, 2025, in eBioMedicine . LIMITATIONS: Individuals with more severe symptoms may have been particularly motivated to participate, introducing selection bias. Additionally, as most biomarker measurements were taken long after participants' initial infection and only a few participants had recent infections, the ability to identify associations specific to the acute phase was likely diminished. DISCLOSURES: This study received funding from the French Ministry of Health and Prevention and the French Ministry of Higher Education, Research and Innovation. Two authors disclosed receiving financial support from Gilead, ViiV, MSD, Moderna, or Pfizer or nonfinancial support from Nordic Pharma France.